, stem cells and pay-to-participate clinical studies

Written by Regenerative Medicine

In this Regenerative Medicine perspective, Leigh Turner discusses whether better screening of clinical trials on is required and what needs to be done to protect patients. Numerous US businesses that engage in direct-to-consumer advertising of stem cell interventions that are not US FDA-approved also recruit clients by listing ‘pay-to-participate’ studies listed on In this Regenerative Medicine perspective, learn why individuals considering enrolling in such studies and NIH officials responsible for overseeing the database need to be aware that some businesses are using the registry to promote unapproved stem cell interventions that study subjects are charged to receive.  Read...

To view this content, please register now for access

It's completely free